Showing results (2481-2490 of 2,542) with videos related to

Sort By:
Pageof 255
Antimicrobial Agents and Chemotherapy|February 23, 2012
Novel N-benzoyl-2-hydroxybenzamide disrupts unique parasite secretory pathwayAlina Fomovska, Qingqing Huang, Kamal El Bissati, et al.
Cell Death and Differentiation|April 9, 2025
Re-appraising assays on permeabilized blood cancer cells testing venetoclax or other BH3 mimetic agents selectively targeting pro-survival BCL2 proteinsJia-Nan Gong, Tirta M Djajawi, Donia M Moujalled, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 18, 2017
Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin LymphomaMatthew S Davids, Andrew W Roberts, John F Seymour, et al.
Blood|October 11, 2022
Acquired mutations in BAX confer resistance to BH3-mimetic therapy in acute myeloid leukemiaDonia M Moujalled, Fiona C Brown, Chong Chyn Chua, et al.
ACS Infectious Diseases|June 15, 2021
Screening a Library of FDA-Approved and Bioactive Compounds for Antiviral Activity against SARS-CoV-2Scott B Biering, Erik Van Dis, Eddie Wehri, et al.
British Journal of Cancer|May 6, 2026
Runx1 and Runx2 act in concert to suppress Wnt/β-catenin-driven mammary tumourigenesisAlessandra I Riggio, Kerri Sweeney, Robin Shaw, et al.
Journal of Cardiac Failure|January 4, 2026
Mean Arterial Pressure and Mortality in Infarction-Related Cardiogenic Shock with and without Cardiac Arrest: A Meta-AnalysisS Ten Berg, M Bogerd, E J Peters, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 2, 2018
Venetoclax for Patients With Chronic Lymphocytic Leukemia With 17p Deletion: Results From the Full Population of a Phase II Pivotal TrialStephan Stilgenbauer, Barbara Eichhorst, Johannes Schetelig, et al.
The Lancet. Oncology|January 17, 2017
Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b studyJohn F Seymour, Shuo Ma, Danielle M Brander, et al.
Nature Cancer|January 29, 2024
Mitochondrial DNA mutations drive aerobic glycolysis to enhance checkpoint blockade response in melanomaMahnoor Mahmood, Eric Minwei Liu, Amy L Shergold, et al.
Pageof 255